We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

Back to rankings

1 hedge funds and large institutions have $34.3M invested in Ariad Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 191 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% less funds holding in top 10

Funds holding in top 10: 9 → 1 (-8)

98% less capital invested

Capital invested by funds: $2.13B → $34.3M (-$2.09B)

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 191

100% less funds holding

Funds holding: 200 → 1 (-199)

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.02%
Holding in Top 10
1
Holding in Top 10 Change
-8
Holding in Top 10 Change %
-88.89%
% of All Funds
0.02%
New
1
Increased
–
Reduced
–
Closed
191
Calls
$31K
Puts
–
Net Calls
+$31K
Net Calls Change
+$16.5M

Top Buyers

Rank Fund Capital Flow
1
FPF
FNY Partners Fund
New York
+$32M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$225M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$218M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$182M
4
SCM
Sarissa Capital Management
Connecticut
-$160M
5
State Street
State Street
Massachusetts
-$97.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCA
126
Gideon Capital Advisors
New York
– -$365K -29,323 Closed
SEI Investments
127
SEI Investments
Pennsylvania
– -$334K -26,816 Closed
Creative Planning
128
Creative Planning
Kansas
– -$326K -26,210 Closed
NPC
129
National Planning Corporation
California
– -$583K -24,500 Closed
Commonwealth Equity Services
130
Commonwealth Equity Services
Massachusetts
– -$291K -23,354 Closed
AB
131
Amalgamated Bank
New York
– -$271K -21,745 Closed
Canada Life
132
Canada Life
Manitoba, Canada
– -$263K -21,040 Closed
CWM
133
Cornerstone Wealth Management
Missouri
– -$260K -21,000 Closed
AG
134
Aperio Group
California
– -$260K -20,867 Closed
Franklin Resources
135
Franklin Resources
California
– -$256K -20,554 Closed
Prudential Financial
136
Prudential Financial
New Jersey
– -$251K -20,175 Closed
HVIA
137
Hudson Valley Investment Advisors
New York
– -$234K -20,000 Closed
RCAG
138
Rehmann Capital Advisory Group
Michigan
– -$249K -20,000 Closed
TI
139
Turner Investments
Pennsylvania
– -$249K -20,000 Closed
TRCT
140
Tower Research Capital (TRC)
New York
– -$224K -18,005 Closed
TI
141
Telemetry Investments
New York
– -$218K -17,500 Closed
Barclays
142
Barclays
United Kingdom
– -$216K -17,361 Closed
BlackRock
143
BlackRock
New York
– -$210K -16,920 Closed
Ohio Public Employees Retirement System (OPERS)
144
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$403K -16,800 Closed
FAM
145
Formidable Asset Management
Ohio
– -$202K -16,266 Closed
BFM
146
Boothbay Fund Management
New York
– -$201 -16,161 Closed
PNC Financial Services Group
147
PNC Financial Services Group
Pennsylvania
– -$194K -15,640 Closed
TSS
148
Two Sigma Securities
New York
– -$193K -15,539 Closed
Neuberger Berman Group
149
Neuberger Berman Group
New York
– -$193K -15,500 Closed
AIP
150
Ameritas Investment Partners
Nebraska
– -$190K -15,280 Closed
4 5
6
7 8

ARIA Hedge Fund Activity: Q1 2017 in Review

1 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q1 2017, worth a combined $34.3M — down 98% from $2.13B a quarter earlier.

Sellers outnumbered buyers: 191 funds closed out of ARIA and 1 opened new positions — a net loss of 190 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was FNY Partners Fund, opening a new position worth an estimated $32M. The largest seller was Fidelity Investments, exiting entirely with an estimated $225M sold.

  • 1 institutional investor held Ariad Pharmaceuticals Inc (ARIA) as of Q1 2017, down from 200 in Q4 2016.
  • Funds reported $34.3M of Ariad Pharmaceuticals Inc stock for Q1 2017, down 98% quarter-over-quarter.
  • 1 fund opened new Ariad Pharmaceuticals Inc positions in Q1 2017 and 191 closed out, a net change of -190 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q1 2017 was FNY Partners Fund, an estimated $32M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q1 2017 was Fidelity Investments, an estimated $225M sold.

Based on aggregated 13F filings for Q1 2017.